

Express Mail Label N . EL 831678235 US
Date of Deposit: October 4, 2001

COPY

Page 1 of 2


OCT 09 2001
TECH CENTER 1600/2900

Modified Form 1449/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/724,842
Filing Date	November 28, 2000
First Named Inventor	Chalifour
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	14445-501 (NCHEM-1)



U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
ST	A7	5,753,624	05/19/98	McMichael <i>et al</i>	514	12	
	A8	5,514,548	05/07/96	Krebber <i>et al</i>	435	6	
	A9	5,869,093	02/09/99	Weiner <i>et al</i>	424	451	
	A10	5,470,951	11/28/95	Roberts	530	330	
ST	A11	5,652,334	07/29/97	Roberts	530	330	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
ST	B11	WO 95/05849	M&E Biotech A/S	02/03/95		
	B12	WO 00/20027	M&E Biotech A/S	13/04/00		
	B13	EP 0752886B1	M&E Biotech A/S	28/01/98		
	B14	WO 95/31996	Milkhaus Laboratory	30/11/95		
	B15	WO 95/05393	Hoess <i>et al.</i>	23/02/95		
	B16	WO 96/13583	Pack <i>et al</i>	09/05/96		
	B17	WO 98/02462	Plückthun	22/01/98		
	B18	WO 99/06587	Rudert <i>et al.</i>	11/02/99		
	B19	WO 97/32017	Ilag <i>et al.</i>	04/09/97		
	B20	WO 97/08320	Knappik <i>et al.</i>	06/03/97		
	B21	WO 00/68263	Neurochem Inc.	16/11/00		
	B22	WO 98/08868	Praecis Pharm Inc.	05/03/98		
	B23	WO 96/28471	Pharmaceutical Peptides Inc.	19/09/96		
	B24	WO 97/21728	Karolinska Innovations AB	19/06/97		
	B25	WO 95/08999	Roberts	06/04/95		
ST	B26	WO 96/37621	Pack <i>et al.</i>	28/11/96		



TECH CENTER 1600/2900

RECEIVED
OCT 09 2001

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
8	C1	Younkin, "Amyloid beta vaccination: reduced plaques and improved cognition", Nat. Med. 2001 Jan; 7(1):18-9.
	C2	Morgan <i>et al.</i> , "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature, 2000 Dec. 21-28;408(6815):982-5.
	C3	Pearson <i>et al.</i> , "Beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," Nature, 2000 Dec. 21-28; 408(6815):979-82.
	C4	Schenk <i>et al.</i> , Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 1999 Jul. 8; 400(6740):173-7.
	C5	Bard <i>et al.</i> , "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nat. Med. 2000 Aug; 6(8):916-9.
	C6	DeMattos <i>et al.</i> , "Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease," Proc. Natl. Acad. Sci. USA 2001 Jul. 3 [ebpub ahead of print]
	C7	Frenkel, "Immunization against Alzheimer's beta-amyloid plaques via EFRH phageadministration," Proc. Natl. Acad. Sci. USA 2000 Oct. 10;97(21):11455-9.
	C8	Frenkel, "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine 2001 Mar. 21;19(17-19):2615-9.
	C9	Van Regenmortel <i>et al.</i> , "D-peptides as immunogens and diagnostic reagents," Curr. Opin. Biotechnol. 1998; Aug; 9(4):377-82.
	C10	Sela <i>et al.</i> , "Different roles of D-amino acids in immune phenomena," FASEB J 199 May; 11(6):449-56.
	C11	Tjernberg, <i>et al.</i> , "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol. Chem. 1997 Jul. 11; 272(28):17894.
	C12	Tjernberg <i>et al.</i> , "Arrest of beta-amyloid fibril formation by a pentapeptide ligand," J. Biol. Chem. 1996 Apr. 12; 271(15):8545-8.
	C13	Tjernberg, <i>et al.</i> , "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol. Chem. 1997 May 9; 272(19):12601-12605.
	C14	Giulian, "The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer disease," J. Biol. Chem. 1998 Nov. 6; 273 (45):29719-29726.
	C15	Flood <i>et al.</i> , "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic affect of amyloid B protein," Proc. Natl. Acad. Sci. USA 1994; 91:380-384.
	C16	Findeis <i>et al.</i> , "Modified peptide inhibitors of amyloid B-peptide polymerization," Biochemistry 1999; 38:6791-6800.
	C17	Benkirane <i>et al.</i> , "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," The Journal of Biological Chemistry 1993; 268 (23):26279-26285.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	8-27-02
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.